Ice Pond Lane Advisers’s Travere Therapeutics TVTX Stock Holding History

Ice Pond Lane Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-518,354	Closed	-$10.9M	–	7
2017 Q4	$10.9M	Hold	518,354	–	–	7.45%	8
2017 Q3	$12.9M	Hold	518,354	–	–	4.91%	10
2017 Q2	$10.1M	Hold	518,354	–	–	5.76%	11
2017 Q1	$9.57M	Hold	518,354	–	–	2.5%	12
2016 Q4	$9.81M	Buy	+518,354	New	+$10.6M	1.48%	11

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ice Pond Lane Advisers's TVTX Position: Q1 2018 in Review

Ice Pond Lane Advisers sold out of Travere Therapeutics (TVTX) in Q1 2018, closing a stake of 518,354 shares — an estimated $10.9M sold.

Ice Pond Lane Advisers first reported a position in TVTX in Q4 2016 and held it in 5 quarters. The position peaked at $12.9M in Q3 2017. 119 funds tracked by Wall St. Rank hold TVTX as of Q1 2018.

Ice Pond Lane Advisers reported no remaining Travere Therapeutics position as of Q1 2018 after selling out during the quarter.
Ice Pond Lane Advisers sold 518,354 Travere Therapeutics shares in Q1 2018, an estimated $10.9M.
Ice Pond Lane Advisers first reported a position in Travere Therapeutics in Q4 2016 and held it in 5 quarters.
Ice Pond Lane Advisers's Travere Therapeutics position peaked at $12.9M in Q3 2017.
119 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2018.

Based on Ice Pond Lane Advisers's 13F filing for Q1 2018, filed 15 May 2018.